

- C. Qualaquin[®] (quinine)
 - i. New Clinical PA Criteria
 - ii. *Public Comment
 - iii. Board Discussion/Action

- D. Crinone[®] (progesterone)
 - i. New Clinical PA Criteria
 - ii. *Public Comment
 - iii. Board Discussion/Action

- E. Humira[®] (adalimumab)
 - i. Revised Clinical PA Criteria
 - ii. *Public Comment
 - iii. Board Discussion/Action

- F. Amevive[®] (alefacept)
 - i. Revised Clinical PA Criteria
 - ii. *Public Comment
 - iii. Board Discussion/Action

- G. Remicade[®] (infliximab)
 - i. Revised Clinical PA Criteria
 - ii. *Public Comment
 - iii. Board Discussion/Action

- H. Simponi[®] (golimumab)
 - i. Revised Clinical PA Criteria
 - ii. *Public Comment
 - iii. Board Discussion/Action

- I. Stelara[®] (ustekinumab)
 - i. Revised Clinical PA Criteria
 - ii. *Public Comment
 - iii. Board Discussion/Action

- J. Methadose[®] (Methadone)
 - i. *Public Comment
 - ii. Board Discussion/Action

- K. Rosiglitazone Products (Avandia[®] (rosiglitazone), Avandamet[®] (rosiglitazone/metformin), Avandaryl[®] (rosiglitazone/glimepiride))
 - i. *Public Comment
 - ii. Board Discussion/Action

*Public Comment is limited to five minutes per product; additional time will be allowed at the Board's discretion. Informal comments will be accepted from members of the audience at various points in the agenda.

**** This agenda is subject to change.**

- L. Single-source prescription limit
 - i. Review Exemptions
 - ii. *Public Comment
 - iii. Board Discussion/Action

- M. Health Information Designs, Inc. (HID)
 - i. Intervention Outcomes
 - ii. Academic Detailing Visits

V. Public Comment

VI. Adjourn

**Lunch will be provided for DUR Board Members
NEXT MEETING: April 13, 2011**

*Public Comment is limited to five minutes per product; additional time will be allowed at the Board's discretion. Informal comments will be accepted from members of the audience at various points in the agenda.

**** This agenda is subject to change.**